Ocugen, Inc. Common Stock (OCGN)
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies and vaccines for rare and underserved diseases. It aims to leverage its expertise in gene therapy, immunology, and vaccine development to address medical needs that lack effective treatments. The company has been involved in COVID-19 vaccine development and research for other therapeutic areas.
Company News
Ocugen announced a licensing agreement with Kwangdong Pharmaceutical for OCU400, an investigational drug targeting retinitis pigmentosa, potentially earning up to $7.5 million upfront and future royalties of 25% on net sales in South Korea.
Ocugen, a biotechnology company focused on gene therapies for blindness diseases, closed a $20 million registered direct offering with Janus Henderson Investors, selling 20 million shares and warrants at $1.00 per share.
Ocugen's shares are trading lower after the company announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
Here's 3 strategies to use when trading options with penny stocks The post Here’s 3 Strategies for Options Trading With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
